0J2O logo

Halozyme Therapeutics LSE:0J2O Stock Report

Last Price

US$48.29

Market Cap

US$6.2b

7D

0.5%

1Y

20.1%

Updated

03 Dec, 2024

Data

Company Financials +

Halozyme Therapeutics, Inc.

LSE:0J2O Stock Report

Market Cap: US$6.2b

0J2O Stock Overview

A biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. More details

0J2O fundamental analysis
Snowflake Score
Valuation6/6
Future Growth5/6
Past Performance5/6
Financial Health3/6
Dividends0/6

Halozyme Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Halozyme Therapeutics
Historical stock prices
Current Share PriceUS$48.29
52 Week HighUS$65.40
52 Week LowUS$33.22
Beta1.24
11 Month Change-15.48%
3 Month Change-21.57%
1 Year Change20.12%
33 Year Change47.35%
5 Year Changen/a
Change since IPO154.95%

Recent News & Updates

Recent updates

Shareholder Returns

0J2OGB BiotechsGB Market
7D0.5%1.4%0.1%
1Y20.1%-12.9%8.5%

Return vs Industry: 0J2O exceeded the UK Biotechs industry which returned -12.9% over the past year.

Return vs Market: 0J2O exceeded the UK Market which returned 8.5% over the past year.

Price Volatility

Is 0J2O's price volatile compared to industry and market?
0J2O volatility
0J2O Average Weekly Movement8.8%
Biotechs Industry Average Movement7.5%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.3%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0J2O's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0J2O's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
1998373Helen Torleyhalozyme.com

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product.

Halozyme Therapeutics, Inc. Fundamentals Summary

How do Halozyme Therapeutics's earnings and revenue compare to its market cap?
0J2O fundamental statistics
Market capUS$6.18b
Earnings (TTM)US$392.47m
Revenue (TTM)US$947.36m

15.8x

P/E Ratio

6.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0J2O income statement (TTM)
RevenueUS$947.36m
Cost of RevenueUS$249.60m
Gross ProfitUS$697.75m
Other ExpensesUS$305.29m
EarningsUS$392.47m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)3.08
Gross Margin73.65%
Net Profit Margin41.43%
Debt/Equity Ratio332.3%

How did 0J2O perform over the long term?

See historical performance and comparison